More than a decade ahead of their patents’ expiration dates, Gilead Sciences is releasing authorized generics of two of its hepatitis C drugs. The launch is planned to happen more than a decade ahead ...

Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...

C++ templates are all about generic programming, but not the type of generics you may be familiar with from C# and Java. This is the first in a series on C++ generic programming. I'll start with an ...

Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...

Watson Pharmaceuticals (NYSE:WPI) received approval from the U.S. Food and Drug Administration for its generic version of a drug to treat C. difficile. Watson submitted an abbreviated new drug ...

For the past three years, various governments and patient advocacy groups have clamored for lower-cost hepatitis C medicines, given the high cure rate for these pricey new drugs. Now, a new study ...

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large ...